Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were ...

Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $5 with highest upside potential. ModeX Therapeutics Inc., an ...

Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...

New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma ...

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported third-quarter ...

Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you ...

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a license and collaboration deal with OPKO Health’s (Nasdaq: ...

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved the label expansion of PD-1 inhibitor Libtayo (cemiplimab-rwlc). Libtayo is now approved as an adjuvant treatment for adult ...

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 ...

Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.67%, the company showcases ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter.